antihypertensive medications
Recently Published Documents


TOTAL DOCUMENTS

966
(FIVE YEARS 393)

H-INDEX

47
(FIVE YEARS 9)

Author(s):  
Marc F. Österdahl ◽  
Sarah-Jo Sinnott ◽  
Ian Douglas ◽  
Andrew Clegg ◽  
Laurie Tomlinson ◽  
...  

2022 ◽  
Vol 8 ◽  
Author(s):  
Alun D. Hughes ◽  
Sophie V. Eastwood ◽  
Therese Tillin ◽  
Nish Chaturvedi

Objectives:We characterised differences in BP control and use of antihypertensive medications in European (EA), South Asian (SA) and African-Caribbean (AC) people with hypertension and investigated the potential role of type 2 diabetes (T2DM), reduced arterial compliance (Ca), and antihypertensive medication use in any differences.Methods:Analysis was restricted to individuals with hypertension [age range 59–85 years; N = 852 (EA = 328, SA = 356, and AC =168)]. Questionnaires, anthropometry, BP measurements, echocardiography, and fasting blood assays were performed. BP control was classified according to UK guidelines operating at the time of the study. Data were analysed using generalised structural equation models, multivariable regression and treatment effect models.Results:SA and AC people were more likely to receive treatment for high BP and received a greater average number of antihypertensive agents, but despite this a smaller proportion of SA and AC achieved control of BP to target [age and sex adjusted odds ratio (95% confidence interval) = 0.52 (0.38, 0.72) and 0.64 (0.43, 0.96), respectively]. Differences in BP control were partially attenuated by controlling for the higher prevalence of T2DM and reduced Ca in SA and AC. There was little difference in choice of antihypertensive agent by ethnicity and no evidence that differences in efficacy of antihypertensive regimens contributed to ethnic differences in BP control.Conclusions:T2DM and more adverse arterial stiffness are important factors in the poorer BP control in SA and AC people. More effort is required to achieve better control of BP, particularly in UK ethnic minorities.


Author(s):  
G. K. Mini ◽  
Thirunavukkarasu Sathish ◽  
Prabhakaran Sankara Sarma ◽  
Kavumpurathu Raman Thankappan

Background The control of hypertension is low in low‐ and middle‐income countries like India. We evaluated the effects of a nurse‐facilitated educational intervention in improving the control rate of hypertension among school teachers in India. Methods and Results This was a cluster‐randomized controlled trial involving 92 schools in Kerala, which were randomly assigned equally into a usual care group and an intervention group. Participants were 402 school teachers (mean age, 47 years; men, 29%) identified with hypertension. Participants in both study groups received a leaflet containing details of a healthy lifestyle and the importance of regular intake of antihypertensive medication. In addition, the intervention participants received a nurse‐facilitated educational intervention on hypertension control for 3 months. The primary outcome was hypertension control. Key secondary outcomes included systolic blood pressure, diastolic blood pressure, and the proportion of participants taking antihypertensive medications. For the primary outcome, we used mixed‐effects logistic regression models. Two months after a 3‐month educational intervention, a greater proportion of intervention participants (49.0%) achieved hypertension control than the usual care participants (38.2%), with an odds ratio of 1.89 (95% CI, 1.06–3.35), after adjusting for baseline hypertension control. The odds of taking antihypertensive medications were 1.6 times higher in the intervention group compared with the usual care group (odds ratio, 1.62; 95% CI, 1.08–2.45). The reduction in mean systolic blood pressure was significantly greater in the intervention group by 4.2 mm Hg (95% CI, −7.2 to −1.1) than in the usual care group. Conclusions A nurse‐facilitated educational intervention was effective in improving the control and treatment rates of hypertension as well as reducing systolic blood pressure among schoolteachers with hypertension. Registration URL: https://www.ctri.nic.in ; Unique Identifier: CTRI/2018/01/011402.


2022 ◽  
Vol 12 (1) ◽  
pp. 87
Author(s):  
Sang Ho Oh ◽  
Su Jin Lee ◽  
Jongyoul Park

Precision medicine is a new approach to understanding health and disease based on patient-specific data such as medical diagnoses; clinical phenotype; biologic investigations such as laboratory studies and imaging; and environmental, demographic, and lifestyle factors. The importance of machine learning techniques in healthcare has expanded quickly in the last decade owing to the rising availability of vast multi-modality data and developed computational models and algorithms. Reinforcement learning is an appealing method for developing efficient policies in various healthcare areas where the decision-making process is typically defined by a long period or a sequential process. In our research, we leverage the power of reinforcement learning and electronic health records of South Koreans to dynamically recommend treatment prescriptions, which are personalized based on patient information of hypertension. Our proposed reinforcement learning-based treatment recommendation system decides whether to use mono, dual, or triple therapy according to the state of the hypertension patients. We evaluated the performance of our personalized treatment recommendation model by lowering the occurrence of hypertension-related complications and blood pressure levels of patients who followed our model’s recommendation. With our findings, we believe that our proposed hypertension treatment recommendation model could assist doctors in prescribing appropriate antihypertensive medications.


2022 ◽  
Vol 9 ◽  
pp. 205435812110692
Author(s):  
Amit X. Garg ◽  
Meaghan Cuerden ◽  
Hector Aguado ◽  
Mohammed Amir ◽  
Emilie P. Belley-Cote ◽  
...  

Background: Most patients who take antihypertensive medications continue taking them on the morning of surgery and during the perioperative period. However, growing evidence suggests this practice may contribute to perioperative hypotension and a higher risk of complications. This protocol describes an acute kidney injury substudy of the Perioperative Ischemic Evaluation-3 (POISE-3) trial, which is testing the effect of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy in patients undergoing noncardiac surgery. Objective: To conduct a substudy of POISE-3 to determine whether a perioperative hypotension-avoidance strategy reduces the risk of acute kidney injury compared with a hypertension-avoidance strategy. Design: Randomized clinical trial with 1:1 randomization to the intervention (a perioperative hypotension-avoidance strategy) or control (a hypertension-avoidance strategy). Intervention: If the presurgery systolic blood pressure (SBP) is <130 mmHg, all antihypertensive medications are withheld on the morning of surgery. If the SBP is ≥130 mmHg, some medications (but not angiotensin receptor blockers [ACEIs], angiotensin receptor blockers [ARBs], or renin inhibitors) may be continued in a stepwise manner. During surgery, the patients’ mean arterial pressure (MAP) is maintained at ≥80 mmHg. During the first 48 hours after surgery, some antihypertensive medications (but not ACEIs, ARBs, or renin inhibitors) may be restarted in a stepwise manner if the SBP is ≥130 mmHg. Control: Patients receive their usual antihypertensive medications before and after surgery. The patients’ MAP is maintained at ≥60 mmHg from anesthetic induction until the end of surgery. Setting: Recruitment from 108 centers in 22 countries from 2018 to 2021. Patients: Patients (~6800) aged ≥45 years having noncardiac surgery who have or are at risk of atherosclerotic disease and who routinely take antihypertensive medications. Measurements: The primary outcome of the substudy is postoperative acute kidney injury, defined as an increase in serum creatinine concentration of either ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours of randomization or ≥50% within 7 days of randomization. Methods: The primary analysis (intention-to-treat) will examine the relative risk and 95% confidence interval of acute kidney injury in the intervention versus control group. We will repeat the primary analysis using alternative definitions of acute kidney injury and examine effect modification by preexisting chronic kidney disease, defined as a prerandomization estimated glomerular filtration rate <60 mL/min/1.73 m2. Results: Substudy results will be analyzed in 2022. Limitations: It is not possible to mask patients or providers to the intervention; however, objective measures will be used to assess acute kidney injury. Conclusions: This substudy will provide generalizable estimates of the effect of a perioperative hypotension-avoidance strategy on the risk of acute kidney injury.


2021 ◽  
Vol 10 (24) ◽  
pp. 5921
Author(s):  
Arrigo F. G. Cicero ◽  
Federica Fogacci ◽  
Elisabetta Rizzoli ◽  
Sergio D’Addato ◽  
Claudio Borghi

The aim of this study was to comparatively evaluate clinical, laboratory and hemodynamic effects on the long term of different triple combination antihypertensive medications in a well-characterized Italian cohort. We considered the data of a subset of Brisighella Heart Study (BHS) participants who were consecutively evaluated in three epidemiological surveys between 2012 and 2020. For the current analysis, we excluded normotensive subjects, patients treated with <3 or ≥3 antihypertensive drugs without taking angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), calcium-channel blockers (CCB) and/or thiazide/thiazide-like diuretics. The remaining participants were divided into three groups depending on whether they were treated with Perindopril/Amlodipine/Indapamide, ACE-inhibitors (other than perindopril)/CCBs/Thiazide or ARBs/CCBs/Thiazide, either with separate drugs or fixed pill combinations. A further group of age- and sex-matched volunteers was selected as control and included patients receiving other antihypertensive treatments. The long-term (12 years) effects of the different antihypertensive treatments were compared among the pre-defined groups. During the observation period, there was a trend towards increase in both systolic and diastolic blood pressure (BP) in all the investigated subgroups (p for trend <0.05), but in the subgroup of patients treated with Perindopril/Amlodipine/Indapamide, such increase was significantly lower than in the other groups (p < 0.05). The combination treatment with renin-angiotensin system (RAS) modulators, CCBs and thiazide/thiazide-like diuretics was associated with significantly lower diastolic BP (p < 0.05) and more strictly controlled lipid pattern than other triple combination of anti-hypertensive medications. Patients treated with Perindopril/Amlodipine/Indapamide did not experience any age-related increase in serum levels of total cholesterol. Moreover, during the follow up none of them developed type 2 diabetes, nor had a need for a greater number of antihypertensive drugs to improve BP control, mainly because of a more stable BP control. Based on our observations, combination treatment with RAS modulators, amlodipine and thiazides/thiazide-like diuretics is more effective than other triple antihypertensive medications for lowering the diastolic BP and has a better impact on serum lipids. Perindopril/Amlodipine/Indapamide is associated with more protective metabolic profile than any other considered combination antihypertensive medications.


2021 ◽  
Vol 10 (6) ◽  
pp. 3853-3855
Author(s):  
M R Suchitra

Banana fruit is one of the commonly taken foods in many parts of the world. The fruit is known for its high potassium content. We wished to study the potassium content of eleven types of ripe banana fruit available in the cauvery delta region of South India. We measured two values in each of the eleven types of banana fruit. We found the mean varied from 460.75mg/100gm in the Rasthali variety to 921.75 in the karpura valli variety. The potassium binding capacity of the soil and the fertilizers pumped may influence the values. The literature which presently describes the values between 200 to 400mg/100g cautions the use of bananas in patients taking antihypertensive medications like enalapril and in patients with renal dysfunction. Our study which shows the values to be double the described ones, will throw light on additional caution in such cases. We admit that there was no soil study in this work which can influence the potassium content. Before any dietetic advice on the intake of potassium, the bananas of the concerned geographical area and such high potassium values should be taken into account. When the needs to cater the patients of potassium arise in uncomplicated hypertension, the varieties karpuravalli and peyampalam can be considered.


Author(s):  
David E. Kandzari

Motivated by the persistence of uncontrolled blood pressure and its public health impact, the development and evaluation of device-based therapies for hypertension has advanced at an accelerated pace to complement pharmaceutical and lifestyle intervention strategies. Countering widespread interest from early studies, the lack of demonstrable efficacy for renal denervation (RDN) in a large, sham-controlled randomized trial motivated revision of trial design and conduct to account for confounding variables of procedural technique, medication variability, and selection of both patients and end points. Now amidst varied trial design and methods, several sham-controlled, randomized trials have demonstrated clinically meaningful reductions in blood pressure with RDN. With this momentum, additional studies are underway to position RDN as a potential part of standard therapy for the world’s leading cause of death and disability. In parallel, further studies will address unresolved issues including durability of blood pressure lowering and reduction in antihypertensive medications, late-term safety, and impact on clinical outcomes. Identifying predictors of treatment effect and surveys of patient-reported outcomes and treatment preferences are also evolving areas of investigation. Aside from confirmatory studies of safety and effectiveness, these additional studies will further inform patient selection, expand experience with RDN in broader populations with hypertension, and provide guidance to how RDN may be incorporated into treatment pathways.


Author(s):  
ANURADHA VP ◽  
MUHAS C ◽  
ANJALI SRUTHY S

Objective: The objective of the study is to assess drug use pattern of antihypertensive medications in hypertensive patients. Methods: It is a prospective cross-sectional study conducted in the outpatient dispensary, Government Medical College, Thiruvananthapuram for the period of 6 months from January 2019 to June 2019. About 500 prescriptions of patients visiting outpatient dispensary with an antihypertensive prescription were enrolled for the study. Drug use patterns of different classes of antihypertensive medications were analyzed from individual prescriptions. Results: A total of 500 patients were included in this study, among which 281 were male (56.2%) and 219 (43.8%) were female. In 500 patients, 133 patients were treated with monotherapy. In that 42.1% of patients were treated with amlodipine, 28.57% of patients were treated with losartan. In combination therapy most commonly used was double therapy (42.8%) followed by triple therapy (24.2%). Calcium Channel Blockers (56.2%) was most prescribed class of drug followed by Angiotensin Receptor Blockers. Conclusion: This study reveals that calcium channel blockers as most prescribed class of antihypertensive and Amlodipine was the most prescribed antihypertensive. In our study, most of the patients were treated with combination therapy in that double drug therapy was most common. There is a chance of various medication errors, development of adverse drug reaction as majority (290) of patients belong to age above 60 and chances of getting error also increases as combination therapy is most used. Therefore close monitoring is required for such patients.


2021 ◽  
Author(s):  
Mir Hossain

UNSTRUCTURED Hypertension is considered as a comorbid condition for the novel coronavirus 2019 (COVID-19). However, there are no reports of “Hypertension crisis” as a presentation or comorbidity of the COVID-19 infection in pediatric patients. In this retrospective observational study, we collected data from total six pediatric patients, diagnosed with confirmed COVID-19 positive who had presented with acute severe hypertension. The mean age of patients was 4.2 years. Four cases were with newly diagnosed nephrotic syndrome and two with chronic kidney disease who were on regular dialysis with no edema or sign of fluid overload, were enrolled. The lowest and highest systolic blood pressures at the time of admission were 160 mmHg and 200 mmHg, respectively. The diastolic blood pressures were between 100-155 mmHg. All patients treated with Labetalol infusion titrated to maximum dosage and continued for at least one week. Our reported children had resistant hypertension and their blood pressure had been controlled with four or five antihypertensive medications. It is crucial to consider the diagnosis of COVID-19 in a patient presenting with a hypertension crisis, even in the absence of classic signs of the virus. Thus from our study we strongly recommend the medical practitioners to consider the probability of COVID-19 infection in cases presenting to the hospital with acute severe hypertension.


Sign in / Sign up

Export Citation Format

Share Document